The Award for the most innovative start-up goes to: Karla Therapeutics
Karla Therapeutics, represented by Simon Loiodice, CEO, received the “Most Innovative Start-up” award.
“Attending the BioFIT meeting was a great opportunity to connect with and gain attention from leading investors as well as potential strategic partners. We’re confident that it will help us maximizing the traction around our project.“
About the poject:
Karla Therapeutics is a drug development company aiming to revolutionize the treatment of mental disorders harnessing the immune system. Mental health corresponds to a major unmet medical need, which is further worsen by the COVID crisis, and a growing problem for the healthcare systems in the world. Current treatment options are decades old, and development of new treatments is hindered by symptom-based definition of psychiatric illnesses. Karla develops drug candidates targeting the immune system rather than the brain directly. The neuro-immune axis is increasingly viewed as critical in brain disorders by the scientific community and Karla’s immuno-centric approach to psychiatry opens the door to potential applications in multiple mental disorders. Karla has data supporting proof-of-concept of its drug candidates as well as implementation of a precision medicine strategy. The young biotech was founded in 2022 and is currently looking to raise a seed round.
The Merck Award for the most innovative project goes to: Odimma Therapeutics
Odimma Therapeutics, represented by Jessica Matta, Co-Founder & CEO, received the “Most Innovative Project” award from Merck.
“We are very proud to receive this award. It recognises the great work performed by the odimma therapeutics team and the potential of its innovative personalised immunotherapy platform in oncology. This prize distinguishes Odimma Therapeutics maturity and strengthens our confidence to start clinical trials in 2023.“
About the poject:
Odimma Therapeutics (Strasbourg – France) is a European biotech company with a unique approach in active personalized cancer immunotherapy. By harnessing the ability of the patient’s own immune system to specifically recognize specific markers displayed by the tumor, also called neoantigens, Odimma Therapeutics has designed a potent next-generation precision immunotherapy platform able to induce a powerful cellular immune response against specific tumors markers as well as a strong anti-tumoral effect in several aggressive précoloniale tumor models. By design the personalized product can be produced in a short period of time with a favourable economic profile, with no limits in the number of neoantigens to be targeted thus maximise patient benefit.
Discover below the start-up projects that presented during BioFIT 2022:
Tuesday, November 29th | 9.30 – 10.30 am CET
LIFESPIN GMBH www.lifespin.health Personalised health | Precision medicine | Digital metabolic signature
Collaborative and licensing opportuny presentations
The Award for the most promising technology goes to: Actome
Actome GmbH, represented by Peter Koltay, Co-founder & CEO, received the “Most Promising Technology” award.
“BioFIT 2022 was a great success for Actome! We had a lot of inspiring meetings, made contacts to important partners and presented our PICO products to potential customers. Finally, we did also win the award for the most promising technology which is a great honour for us! We are grateful to the BioFIT team for this award and for the well organised event.”
About the poject:
Actome GmbH is a life-science start-up form Freiburg, Germany adopting digital PCR (dPCR) technology and Next Generation Sequencing (NGS) for the ultra-sensitive measurement of proteins and protein interactions. First products based on the Protein Interaction Coupling (PICO) technology for use on dPCR instruments of QIAGEN have been released already in May this year. Now, the Actome team embarks on developing products for readout by NGS to enable the simultaneous analysis of a large number of proteins and protein interactions in a single assay with hitherto unseen performance.
Discover below the technologies that presented during BioFIT 2022
The Award for the most Innovative Animal Health Project goes to: University of Ljubljana, Faculty of Pharmacy
Urban Košak, Researcher, is the winner of this year’s edition of the Animal Health Presentations, with its project from the University of Ljubjlana, Faculty of Pharmacy.
“BioFIT was an awesome experience because I got the opportunity to present the results of my teams’ research work to representatives of animal and human health pharmaceutical companies. They gave me a lot of invaluable advice that will help me and my team reach our desired professional goals.”
About the poject:
At the Department of Pharmaceutical chemistry at the University of Ljubljana, Faculty of Pharmacy we have developed a new selective butyrylcholinesterase inhibitor that increases brain levels of acetylcholine, the neurotransmitter in the brain responsible for memory and learning. Our compound improves memory, cognitive functions and learning abilities of mice with induced symptoms of Alzheimer’s disease. It is not active only in laboratory animals, but in actual patients. Our inhibitor improves cognitive functions and quality of life of dogs suffering from canine cognitive dysfunction. Most importantly, our compound does not produce the cholinergic adverse effects typical for other drugs that increase brain levels of acetylcholine. We have patented our inhibitor and are looking to license it to an animal or human health pharmaceutical company.
Discover below the animal health projects that presented during BioFIT 2022
With more than 1,000 international actors from 35+ countries, such as big pharma, emerging and small biotech, diagnostic companies, pre-seed / seed / Series A investors, as well as professionals from tech transfer, academia and research institutions, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment rounds in Life Sciences. Learn more
WARNING: Some fraudulent companies are supposedly providing the attendees list of BioFIT. And some are passing themselves off as being BioFIT organisation members and asking you to pay. Please note that the BioFIT team will never sell you the BioFIT attendees list and never ask for your bank account details to make you pay for hotel bookings, exhibition fees or others, and certainly not over the phone.Please be extremely vigilant.
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.